← Back to screener

IONIS PHARMACEUTICALS INC IONS

Rank #2450 · Nasdaq · $7.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
17.0
P/E
-19.6
P/B
12.55
ROE
-63.9%
Op. Margin
-44.9%
Debt Ratio
422%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -19.6x, P/B 12.55x. Ranks in the top 81% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -63.9%. Ranks in the top 88% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 422%. Ranks in the top 77% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆
Excellent

Revenue growth of 34.1% year over year. Ranks in the top 10% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.1B$-0.0B$0.2B$0.2B-22.6125
2012$0.1B$-0.0B$-0.1B$0.2B-44.6183
2013$0.1B$-0.1B$-0.1B$0.2B-71.8199
2014$0.1B$-0.1B$-0.1B$0.4B-67.5124
2015$0.1B$-0.1B$-0.1B$0.3B-35.1271
2016$0.2B$-0.0B$-0.0B$0.2B-22.3372
2017$0.3B$-0.1B$-0.1B$0.1B-26.7816
2018$0.4B$-0.0B$-0.1B$0.3B-5.4341
2019$0.5B$0.0B$0.0B$1.0B6.0141
2020$0.6B$-0.1B$0.3B$1.5B-10.2105
2021$1.1B$0.4B$0.3B$0.7B32.6222
2022$0.7B$-0.2B$-0.4B$0.8B-23.6238
2023$0.8B$-0.0B$-0.0B$0.7B-3.7264
2024$0.6B$-0.4B$-0.3B$0.8B-69.8337
2025$0.8B$-0.4B$-0.4B$0.6B-44.9422

← See the full screener